The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis

Exclusion Criteria

• •(Patient-Generated Subjective Global Assessment, PG-SGA)\>9 or severe malnutrition (weight loss \> 10% or serum albumin \< 30 g/L or body mass index \< 18.5 kg/m2);
• •Patients with severe heart, lung and brain diseases; chronic hepatitis infection, liver cirrhosis, chronic nephritis, kidney dysfunction, etc;
• •Patients with infection-related fever;
• •Patients who are known to be allergic or intolerant to any of the ingredients used in the study;
• •Patients with long-term chronic diarrhea, abdominal pain, constipation or other digestive tract diseases; patients with gastrointestinal symptoms before chemotherapy (≥grade 2 NCI-CTCAE, version 4.0);
• •Synchronously receive other treatments that may cause diarrhea, such as radiotherapy;
• •Patients who take drugs for microecological regulation of digestive tract such as Combined Bifidobacterium, ChangTai oral liquid, etc;
• •Patients take traditional Chinese medicine or antibiotics;
• •Unable to understand and sign the informed consent form;
• •participants in other clinical trials.